Markets:

Overview

News

Currencies

International

Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

3.570 -0.010 (-0.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week ↗

August 25, 2023

Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week.

Via Talk Markets

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗

August 20, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in...

Via Talk Markets

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗

August 13, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD.

Via Talk Markets

Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA ↗

August 10, 2023

Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show:

Via Benzinga

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

August 10, 2023

From atai Life Sciences

Via GlobeNewswire

Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration ↗

August 09, 2023

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its...

Via Benzinga

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

August 08, 2023

From atai Life Sciences

Via GlobeNewswire

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗

July 30, 2023

All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:

Via Talk Markets

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗

July 23, 2023

The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗

July 14, 2023

Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.

Via Talk Markets

Psychedelic Stocks Jumped 10% Last Week ↗

July 09, 2023

The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly

Via Talk Markets

COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital ↗

July 05, 2023

Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist

Via Benzinga

Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗

July 01, 2023

Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...

Via Talk Markets

Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗

June 17, 2023

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.

Via Talk Markets

MAPS' Psychedelic Science 2023: Gov. Polis To Open Event, New Shulgin Compounds To Be Revealed ↗

June 14, 2023

Psychedelic Science, this year’s gathering hosted by the legendary nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its final agenda,...

Via Benzinga

May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗

June 01, 2023

Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.

Via Talk Markets

atai Life Sciences to Participate in Upcoming June Investor Conferences

June 01, 2023

From atai Life Sciences

Via GlobeNewswire

3 Penny Stocks to Make You the Millionaire Next Door ↗

May 25, 2023

Explore the world of high-risk, high-reward top penny stocks to buy and uncover promising investment opportunities.

Via InvestorPlace

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗

May 15, 2023

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...

Via Benzinga

Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials ↗

May 11, 2023

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated...

Via Benzinga

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

May 11, 2023

From atai Life Sciences

Via GlobeNewswire

atai Life Sciences to Participate in Upcoming May Investor Conference

May 02, 2023

From atai Life Sciences

Via GlobeNewswire

April Psychedelic Drug Stocks Recap: The Ups And Downs ↗

April 30, 2023

Via Talk Markets

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

April 28, 2023

From atai Life Sciences

Via GlobeNewswire

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗

April 21, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.